On September 12, 2018 Gen inCode, S.L. acquired the personalized medicine service of the products Cardio inCode®, Lipid inCode®, SudD inCode® and Thrombo inCode®, offered until now by Ferrer inCode.
Gen inCode, made up of individuals previously involved in the development and management of this project, has the experience to carry on providing the service offered up to now.
As a result of this acquisition, as of November 1, 2018, SITAB will be managed by Gen inCode. To continue accessing your patients’ records from the SITAB Gen inCode platform, and get access to possible updates of those reports that emerge from new scientific discoveries, confirm that these documents can be transmitted to Gen inCode by clicking here.